In:
Allergologia et Immunopathologia, Codon Publications, Vol. 51, No. 3 ( 2023-05-01), p. 181-185
Abstract:
Dupilumab is a biologic, acting on IL-4 and IL-13 pathways. Dupilumab has a pediatric indication for treating severe asthma and atopic dermatitis. We report a pediatric case concerning paucisymptomatic, transient, and self-resolving hyperthyroidism. The updated literature includes the case of an adult patient who reported with hyperthyroidism, which was transient and self-resolving. Despite that these cases were transient and self-resolving, we would suggest that thyroid function assessment could be included in the follow-up of patients treated with Dupilumab. Dupilumab discontinuation is not required pending endocrinological assessment, mainly if there is an optimal clinical response to the biologic.
Type of Medium:
Online Resource
ISSN:
0301-0546
DOI:
10.15586/aei.v51i3.786
Language:
Unknown
Publisher:
Codon Publications
Publication Date:
2023
Permalink